

Research and Reviews: Journal of Pharmacology and Toxicological Studies

A Review on Vildagliptin

Sri Chandini K^{1*} and Ram Vinod ND²

¹Andhra University, Visakhapatnam, Andhra Pradesh, India

²Sri Krishna Devaraya University, Anantapur, Andhra Pradesh, India

Review Article

Received: 10/04/2016
Accepted: 12/04/2016
Published: 25/04/2016

*For Correspondence:

K. Sri Chandini, Andhra University, Visakhapatnam, Andhra Pradesh, India

E-mail: srichandini@gmail.com

INTRODUCTION

Vildagliptin (already LAF237, trade names Galvus, Zomelis,) is an oral hostile to hyperglycemic agent (against diabetic medication) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of medications [1]. Vildagliptin hinders the inactivation of GLP-1 and GIP by DPP-4, permitting GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon discharge by the alpha cells of the islets of Langerhans in the pancreas. Vildagliptin has been appeared to lessen hyperglycemia in type 2 diabetes mellitus [2-4]. Unfavorable impacts observed in clinical trials includes queasiness, hypoglycemia, tremor, cerebral pain and dizziness. Uncommon instances of hepatotoxicity have been reported.

There have been case reports of pancreatitis connected with DPP-IV inhibitors. A gathering at UCLA reported increased pre-carcinogenic pancreatic changes in rats and in human organ givers who had been treated with DPP-IV inhibitors [5-18]. In response to these reports, the United States FDA [19-25]. and the European Medicines Agency each attempted autonomous audits of all clinical and preclinical information identified with the conceivable relationship of DPP-IV inhibitors with pancreatic cancer [26-30]. In a joint letter to the New England Journal of Medicines, the organizations expressed that "Both offices concur that declarations concerning a causal relationship between incretin-based medications and pancreatitis or pancreatic malignancy, as communicated as of late in the experimental writing and in the media, are conflicting with the present information [31,9,18]. The structure of vildagliptin is presented in (Figure 1). The FDA and the EMA have not achieved a final conclusion as of now in regards to such a causal relationship [7,12,32-40]. Despite the fact that the totality of the information that have been assessed gives reassurance, pancreatitis will keep on being viewed as a risk connected with these medications until more information are accessible; both organizations keep on investigating this security signal [41-46].




Figure 1: Structure of Vildagliptin.

IUPAC Name	(S)-1-[N-(3-hydroxy-1-adamantyl)glycyl]pyrrolidine-2-carbonitrile
Clinical Data	
Trade names	Galvus
AHFS/Drugs.com	International Drug Names
License data	EU EMA: Galvus
Routes of administration	Oral
Legal status	
Legal status	UK: POM (Prescription only)
Pharmacokinetic data	
Bioavailability	85%
Protein binding	9.30%
Metabolism	Mainly hydrolysis to inactive metabolite; CYP450 not appreciably involved
Biological half-life	2 to 3 hours
Excretion	Renal
Identifiers	

CAS Number	274901-16-5
ATC code	A10BH02 (WHO)
	A10BD08 (WHO) (withmetformin) ^[1]
PubChem	CID 6918537
IUPHAR/BPS	6310
DrugBank	DB04876
ChemSpider	5293734
UNII	I6B4B2U96P
KEGG	D07080
ChEMBL	CHEMBL142703
Synonyms	(2S)-1-{2-[(3-hydroxy-1-adamantyl)amino]acetyl}pyrrolidine-2-carbonitrile
Chemical data	
Formula	C ₁₇ H ₂₅ N ₃ O ₂
Molar mass	303.399 g/mol

Table 1: Vildagliptin Specifications.

RESEARCH DESIGN AND METHODS

This was a twofold visually impaired, randomized, multicenter (**Table 1**)^[47-49], parallel group investigation of a 24-week treatment with 50 mg vildagliptin regularly (n = 177), 100 mg vildagliptin every day (n = 185), or placebo (n = 182) in patients proceeding with a steady metformin measurements regimen ($\geq 1,500$ mg/day) yet accomplishing insufficient glycemic control (A1C 7.5–11%)^[3,8,10,12,24,41,50-52].

RESULTS

The between-treatment contrast (vildagliptin – fake treatment)^[10,43,53-55] in balanced mean change (AM Δ) \pm SE in A1C from pattern to end point was $-0.7 \pm 0.1\%$ (P < 0.001) and $-1.1 \pm 0.1\%$ (P < 0.001) in patients getting 50 or 100 mg vildagliptin every day, individually^[14,23,56-60]. The between-treatment contrast in the AM Δ fasting plasma glucose (FPG)^[61-68] was -0.8 ± 0.3 mmol/l (P = 0.003) and -1.7 ± 0.3 mmol/l (P < 0.001) in patients getting 50 or 100 mg vildagliptin day by day, separately. Unfriendly occasions (AEs) were accounted for by 63.3, 65.0, and 63.5% of patients accepting 50 mg vildagliptin day by day, 100 mg vildagliptin day by day, or fake treatment, individually^[69-74]. Gastrointestinal AEs were accounted for by 9.6 (P = 0.022 versus fake treatment)^[75-82], 14.8, and 18.2% of patients getting 50 mg vildagliptin every day, 100 mg vildagliptin day by day, or fake treatment, separately. One patient in every treatment bunch experienced one gentle hypoglycemic occasion^[5,16,28,80,83-89].

CONCLUSIONS

Vildagliptin is very much endured and creates clinically important, dose related decreases in A1C and FPG as extra treatment in patients with type 2 diabetes insufficiently controlled by metformin^[90-100].

REFERENCES

1. Wild S, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*. 2004;27:1047-1053.
2. Permutt MA, et al. Genetic epidemiology of diabetes. *J Clin Invest*. 2005;115:1431-1439.
3. Yin JY, et al. ABCC1 polymorphism Arg723Gln (2168G> A) is associated with lung cancer susceptibility in a Chinese population. *Clin Exp Pharmacol Physiol*. 2001;38:632-637.
4. Yin JY, et al. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. *Pharmacogenet Genomics*. 2009;19:206-216.
5. Glamoclija U and Jevric-Caušević. A Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics. *Acta Pharm*. 2010;60:387-406.
6. Kirchheiner J, et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. *Clin Pharmacokinet*. 2005;44:1209-1225.
7. Holstein A and Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. *Expert Opin Drug Metab Toxicol*. 2009;5:225-241.
8. Holstein A, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. *Br J Clin Pharmacol*. 2005;60:103-106.
9. Holstein A, et al. Impact of clinical factors and CYP2C9 variants for the risk of severe sulphonylurea-induced hypoglycemia. *Eur J Clin Pharmacol*. 2011;67:471-476.
10. Gloyn AL, et al. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). *Diabet Med*. 2001;18:206-212.
11. Florez JC, et al. Haplotype structure and genotype-phenotype correlations of the sulphonylurea receptor and the islet ATP-sensitive potassium channel gene region. *Diabetes*. 2004;53:1360-1368.
12. Nielsen EM, et al. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. *Diabetes*. 2003;52:573-577.
13. Sesti G, et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulphonylurea in patients with type 2 diabetes. *J Clin Endocrinol Metab*. 2006;91:2334-2339.
14. Pearson ER. Translating TCF7L2: from gene to function. *Diabetologia*. 2009;52:1227-1230.
15. Pearson ER, et al. Variation in TCF7L2 influences therapeutic response to sulphonylureas: a GoDARTs study. *Diabetes*. 2007;56:2178-2182.
16. Rafiq M, et al. Effective treatment with oral sulphonylureas in patients with diabetes due to sulphonylurea receptor 1 (SUR1) mutations. *Diabetes Care*. 2008;31:204-209.
17. Pearson ER, et al. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. *Diabet Med*. 2000;17:543-545.
18. Holstein A and Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. *Exp Clin Endocrinol Diabetes*. 2003;111:405-414.
19. Hu S, et al. The mechanisms underlying the unique pharmacodynamics of nateglinide. *Diabetologia*. 2003;46:M37-43.

20. Yu M, et al. KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. *Clin Pharmacol Ther.* 2010;87:330-335.
21. Foley JE. Vildagliptin - Mode of Action. *Med chem.* 2014;4:439-440.
22. Kwon O, et al. Discovery of DiPeptidyl Peptidase-4 Gene Variants and the Associations with Efficacy of Vildagliptin in Patients with Type 2 Diabetes - A Pilot Study. *J Diabetes Metab.* 2013;S13:006.
23. Hadi NR, et al. Effect of Vildagliptin on Atherosclerosis Progression in High Cholesterol –Fed Male Rabbits. *J Clin Exp Cardiol.* 2013;4:249.
24. Ateyya H. Amelioration of Cyclosporine induced Nephrotoxicity by Dipeptidylpeptidase inhibitor Vildagliptin. Joint International Conference and Expo on Industrial Pharmacy & 5th Global Pharmacovigilance Summit, Dubai, UAE.
25. Kosaraju J. Neuroprotective effects of vildagliptin, a dipeptidyl peptidase-4 inhibitor against streptozotocin induced Alzheimer's disease. 2nd International Conference and Exhibition on Neurology & Therapeutics 2013 Hilton Chicago/Northbrook, Chicago, USA.
26. Wu X, et al. Development of Type-2 Diabetes Mellitus is associated with Low Levels of ApoA1. *J Diabetes Metab.* 2016;7:669.
27. Lakshmi PK, et al. Drug information services to doctors of Karnataka, India. *Indian J Pharmacol.* 2003;35:245-47.
28. Parker PF. The University of Kentucky. Drug Information Centre. *Am J Hosp Pharm.* 1965;22: 42-7.
29. Kalra M, et al. Drug information centers-Need of the hour. *Internationale Pharmaceutica Scientia.* 2011;1:69-76
30. Devi P and George J. Drug information needs of physicians treating diabetic nephropathy in a tertiary care hospital. *Kathmandu University Med J.* 2008;6:23-27
31. Prasad S and Cucullo L (2015) Impact of Tobacco Smoking and Type-2 Diabetes Mellitus on Public Health: A Cerebrovascular Perspective. *J Pharmacovigil.* 2015;S2:e003.
32. Rekha MB, et al. Assessment and Evaluation of Drug Information Needs of Physicians Treating Type-2 Diabetes Mellitus with Co-Existing Hypertension in a Tertiary Care Hospital. *RRJMHS.* 2014;3:146-150.
33. Rao GHR, et al. Clinical Complications of Type-2 Diabetes Mellitus in South Asian and Chinese Populations: An Overview. *J Diabetes Metab.* 2014;5:420.
34. Yin J, et al. Pharmacogenetics of Oral Antidiabetic Drugs: Potential Clinical Application. *Endocrinol Metab Synd.* 2012;S5:003.
35. Rahman MR, et al. Simultaneous Estimation of Antihypertensive and Antidiabetic Drugs by HPLC, JPQA. 2015;1:25-29.
36. Reichal CR, and Rao MG. Anti-diabetic Drugs and Fixed Dose Combination Therapy. *RRJPPS.* 2014;3:55-58.
37. Thakkar V, et al. Examination of intricacies involved in designing of once a day tablet containing newer combination of anti-diabetic drugs for type 2 diabetes. 7th Indo Global Diabetes Summit and Medicare Expo, Bengaluru, India.
38. Pasupuleti VK, et al. Intervention of Nutritional Drink (SAI) in Poorly Controlled Hyperglycemic Patients With Type 2 Diabetes Despite Oral Anti Diabetic Drugs Treatment: Randomized Controlled Trial. 2nd World Congress on Diabetes & Metabolism, Philadelphia Airport Marriott, USA.

39. Naskar S. Complications associated with diabetes and crucial factors for the evaluation of antidiabetic drugs. 3rd World Congress on Diabetes & Metabolism, Marriott Convention Center, Hyderabad, India.
40. Zaini RG and Abdulsatar S. Detection of Undiagnosed Diabetes among Saudi Female at Four Campaigns in Taif City, Saudi Arabia. *J Diabetes Metab.* 2016;7:689.
41. Rachel C, et al. The -765G>C Cyclooxygenase-2 Promoter Polymorphism is associated with Type 2 Diabetes Mellitus, Low High-density Lipoprotein and Manifest Angina. *J Diabetes Metab.* 2016;7:686.
42. Janet LP and LeAnne MH. Validity of the Community Integration Questionnaire as a Measure of Participation in Persons with Diabetes Mellitus. *J Diabetes Metab.* 2016;7:687.
43. Chen C, et al. Elevated Interleukin-17 Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. *Biochem Physiol.* 2016;5:206.
44. Inancli SS, et al. Evaluation of Thyroid Autoimmunity in Gestational Diabetes Mellitus. *J Diabetes Metab.* 2016;7:682.
45. Mehta K and Chavda. Beat Diabetes: Are We Ready? *Gen Med.* 2016;4:e108.
46. Tagliente I, Digilio G, Ullmann N, Solvoll T, Trieste L, et al. (2016) Management and Treatment of Type 1 And 2 Diabetes: State of Art. *Gen Med (Los Angeles)* 4: 259.
47. Bayramova AN. Gastroenterological Diseases as a Complications of Type 2 Diabetes Mellitus. *J Gastrointest Dig Syst.* 2016;6:442.
48. Tang X, et al. A Randomized Controlled Clinical Trial on the Treatment of Type 2 Diabetes with Depression by Wu Ling Capsule. *J Clin Trials.* 2016;6:273.
49. Hernandez HE, et al. Baseline Anemia Analysis of Hispanic Dialysis Patients with and without Type 2 Diabetes. *J Mol Histol Med Physiol.* 2016;1:105.
50. Mitchell S, et al. Women in Control: Pioneering Diabetes Self-Management Medical Group Visits in the Virtual World. *J Clin Trials.* 2016;6:272.
51. Cheekurthy AJP, et al. Prevalence of Type 2 Diabetes Mellitus among Women and the Associated Risk Factors. *RRJNHS.* 2016;2;26-30.
52. Fang W, et al. The Effect on Gut Microbiota Structure of Primarily Diagnosed Type 2 Diabetes Patients Intervened by Sancai Lianmei Particle and Acarbose: A Randomized Controlled Trial. *J Clin Trials.* 2016;6:270.
53. Yadav H, et al. Gut Microbiome Derived Metabolites to Regulate Energy Homeostasis: How Microbiome Talks to Host. *Metabolomics.* 2016;6:e150.
54. Mesquita C, et al. Effect of the Endoplasmic Reticulum Stress on Diabetes Mellitus Type 2 in Hypothalamic Cells. *Endocrinol Metab Syndr.* 2016;5:243.
55. Norouzi Z, et al. The Prevalence of Depression in Patients with Diabetes Mellitus Type II in the Shahid Rahimi Hospital of Khorramabad, Iran. *Epidemiology.* 2016;6:249.
56. Parveen S and Anjum S. To Investigate Prevalence of Diabetes Type 1 and Type 2 in HCV Infected Individuals. *Epidemiology.* 2016;6:246.
57. Szybinski Z. Primary Prevention of Obesity and Type 2 Diabetes Mellitus. *Epidemiology.* 2016;6:243.
58. Demchuk MP, et al. Efficacy of Fetal Stem Cells use in Complex Treatment of Patients with Insulin-resistant Type 2 Diabetes Mellitus. *J Stem Cell Res Ther.* 2016;6:342.
59. Cakir OO, et al. Visceral Fat Volume is a Better Predictor for Insulin Resistance than Abdominal Wall Fat Index in Patients with Prediabetes and Type 2 Diabetes Mellitus. *Intern Med.* 2016;6:220.

60. Raina SK. From NHM to NPCDCS: Epidemiological Transition and Need for a National Program for Diabetes in India. *J Metabolic Syndr.* 2016;5:204.
61. Ignacio BA, et al. Diabetes Mellitus and Neuromuscular Blockade: Review. *J Diabetes Metab.* 2016;7:678.
62. Lambadiari V, et al. Short Term, Low Dose Thyroxin Treatment of Euthyroid Patients with Type 2 Diabetes improves Peripheral Blood Flow and Overall Insulin Sensitivity. *J Diabetes Metab.* 2016;7:677.
63. Berezin AE. Can Osteoprotegerin be a Target of Therapy in Type 2 Diabetes Mellitus? *Metabolomics.* 2016;6:172.
64. Hayashi A and Suganuma N. Physical Activity for Gestational Diabetes Mellitus. *Clinics Mother Child Health.* s2016;13:238.
65. Sunanda T, et al. Role of HbA1c at Admission on Severity and Functional Outcome of Ischemic Stroke in Patients with Diabetes Mellitus. *J Neurol Neurophysiol.* 2016;7:377.
66. Hines TA and Kumar S. Certified Electronic Health Records and Quality of Health Care in Type II Diabetes Mellitus Patients. *J Health Med Informat.* 2016;7:231.
67. Tina L, et al. Diabetes Mellitus and Airway Obstruction: Is there an Association? *Adv Practice Nurs.* 2016;2:116.
68. Demirsoy IH, et al. TCF7L2 rs7903146 Gene Variation Is Associated with Risk of Type 2 Diabetes in Turkish Population. *J Clin Med Genom.* 2016;4:141.
69. Nayeri A, et al. Type 2 Diabetes Mellitus is an Independent Risk Factor for Postoperative Complications in Patients Surgically Treated for Meningioma. *J Neurol Neurophysiol.* 2016;7:368.
70. Merlo S, et al. Polymorphisms rs699 and rs4762 of the Angiotensinogen Gene and Progression of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus. *J Diabetic Complications Med.* 2016;1:107.
71. Kurioka S, et al. Combination Therapy of Pitavastatin and Sitagliptin Improves the Estimated Glomerular Filtration Rate in Patients with Type 2 Diabetes. *J Diabetes Metab.* 2016;7:667.
72. Wamique M and Ali W. CETP Gene and Its Role in Diabetes Mellitus Type II - A Review. *J Community Med Health Educ.* 2016;6:425.
73. Wamique M, Ali W (2016) CETP Gene and Its Role in Diabetes Mellitus Type II - A Review. *J Community Med Health Educ* 6: 425.
74. Lott S. Inpatient Diabetes and the Pharmacist Role. *RRJHCP.* 2016;2:28-29.
75. Abdulrhman MA. Honey as a Sole Treatment of Type 2 Diabetes Mellitus. *Endocrinol Metab Syndr.* 2016;5:232.
76. Jena PK, et al. Influence of Gut Microbiota on Inflammation and Pathogenesis of Sugar Rich Diet Induced Diabetes. *Immunome Res.* 2016;12:109.
77. Lin Y, et al. Discussion of EZSCAN Parameters for Diabetes Screening in Chinese. *Biochem Anal Biochem.* 2016;5:263.
78. Nørgaard SK, et al. Prepregnancy Body Mass Index and Offspring Birth Weight in Women with Type 1 and Type 2 Diabetes. *J Preg Child Health.* 2016;3:244.
79. El-Sappagh S and Elmogy M. A Decision Support System for Diabetes Mellitus Management. *Diabetes Case Rep.* 2016;1:102.
80. Siddique MAH, et al. Comparison of Antioxidative Effects of Biguanides and Sulfonylureas Monotherapy on Total Antioxidant Status in Newly-Diagnosed Patients with Type 2 Diabetes Mellitus. *Diabetes Case Rep.* 2016;1:104.

81. Sharma NR and Rao GHR. Diabetes Management: Expectations and Limitations. *J Diabetes Metab.* 2016;7:662.
82. Piatkiewicz P. Hypoglycemia in Elderly Type 2 Diabetes Patients. *J Clin Diabetes Pract.* 2016;1:e101.
83. Zain M, et al. Association of Family History of Type 2 Diabetes with COMT Gene Polymorphism (I/D) in Pakistani Population. *J Down Syndr Chr Abnorm.* 2016;2:108.
84. Rongies, et al. The Prevalence of Prediabetes in Healthcare Professionals assessed based on Glycated Hemoglobin Levels. *J Diabetes Metab.* 2016;7:660.
85. Huttada L, et al. Enhancing the Activity of Peroxisome Proliferator- Activated Receptor's (PPAR) Activity through Natural Ligand Binding in Diabetes: Substantial Computational Approach. *Nat Prod Chem Res.* 2016;4:213.
86. Nishimura T, et al. Bilirubin as a New Biomarker of Diabetes and its Microvascular Complications. *Biochem Anal Biochem.* 2016;5:245.
87. Batra V and Singh G. A Rare Clinical Presentation of Diabetes Mellitus. *Immunochem Immunopathol.* 2016;2:116.
88. Cardoso C, et al. Cost-effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Portugal. *J Diabetes Metab.* 2016;7:653.
89. Tong CV, et al. Glycemic Variability among Older Adults with Type 2 Diabetes. *J Diabetes Metab.* 2016;7:652.
90. Kelleni MT. Chamomile Tea Potentials in Prevention and Amelioration of Type 2 Diabetes Mellitus. *J Diabetes Metab.* 2016;7:649.
91. Ibrahim SI, et al. Carbonic Anhydrase: A New Therapeutic Target for Managing Diabetes. *J Metabolic Syndr.* 2016;5:196.
92. Bos AJG, et al. Comparing the Prevalence and Drug Treatment Rates of Diabetes, Hypertension and Dyslipidemia between Japan and Brazil, using 2013 National Health Surveys. *J Clin Diabetes Pract.* 2015;1:103.
93. Nicola D and Francesco Z. Future Prospects for the Treatment of Diabetes. *J Clin Diabetes Pract.* 2016;1:e101.
94. Al Busaidi N, et al. Glycemic Control and Co morbidities of Patients with Type 1 and Type 2 Diabetes Referred to the National Diabetes and Endocrine Centre in Muscat, Oman. *J Diabetes Metab.* 2015;6:632.
95. Gomez-Peralta F, et al. Glycemic Control and Hospital Admission Risk in Type 1 Diabetes is Related to the Use of Carbohydrate Counting and Frequency of Self-Monitoring of Blood Glucose: RSD1 Study. *J Diabetes Metab.* 2015;6:628.
96. Raj U, et al. In Silico Identification of Novel Glucagon Receptor Antagonist for the Treatment of Type 2 Diabetes Mellitus. *Enz Eng.* 2015;4:128.
97. Pawar K and Thompkinson DK. Multifunctional Ingredient Dietary Supplement for Management of Hyperglycemic and Hypercholesterolemic Therapy of Diabetes. *J Nutr Food Sci.* 2015;5:439.
98. Eguchi T, et al. The Efficacy of Pioglitazone Treatment in Myotonic Dystrophy Type 1 and Type 2 Diabetes Mellitus Patient. *J Clin Case Rep.* 2015;5:584.
99. El Sayyad HIH, et al. Fish Oil Supplementation Ameliorated Brain Lesions Induced by Diabetes and Hypercholesterolemia in Male Wistar Albino Rats. *Autism.* 2015;5:148.

100. Berezin A. The Rationality to Use of Galectin-3 as Target in Biomarker-Guided Therapy of Type 2 Diabetes Mellitus. *Endocrinol Metab Syndr.* 2016;5:1000217.